Literature DB >> 18712523

Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis.

Hatice Bodur1, Filiz Eser, Sefika Konca, Serpil Arikan.   

Abstract

Infliximab is a chimerical monoclonal antibody currently used in the treatment of various inflammatory diseases. Lupus-like syndrome is a rarely reported adverse event, and generally observed in rheumatoid arthritis cases. We hereby define and describe a case of a lupus-like syndrome, which developed following the 4th infliximab infusion in a 62-year-old patient with ankylosing spondylitis (AS). As far as we acknowledge, the present case is the third AS case with infliximab-induced lupus.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18712523     DOI： 10.1007/s00296-008-0684-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  11 in total

1.  Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab.

Authors:  C Pérez-García; J Maymo; M P Lisbona Pérez; M Almirall Bernabé; J Carbonell Abelló
Journal:  Rheumatology (Oxford)       Date:  2005-11-30       Impact factor: 7.580

2.  Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis.

Authors:  P Pallotta; G Cianchini; M Ruffelli; P Puddu
Journal:  Rheumatology (Oxford)       Date:  2005-11-30       Impact factor: 7.580

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.

Authors:  Min-Jung Kang; You-Hyun Lee; Jisoo Lee
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

5.  Quality indicators, guidelines and outcome measures in ankylosing spondylitis.

Authors:  J Zochling; J Braun
Journal:  Clin Exp Rheumatol       Date:  2007 Nov-Dec       Impact factor: 4.473

6.  Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.

Authors:  J Braun; X Baraliakos; J Listing; C Fritz; R Alten; G Burmester; A Krause; S Schewe; M Schneider; H Sörensen; H Zeidler; J Sieper
Journal:  Ann Rheum Dis       Date:  2007-10-29       Impact factor: 19.103

7.  Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.

Authors:  J C Davis; D M van der Heijde; J Braun; M Dougados; D O Clegg; A J Kivitz; R M Fleischmann; R D Inman; L Ni; S-L Lin; W H Tsuji
Journal:  Ann Rheum Dis       Date:  2007-10-29       Impact factor: 19.103

8.  Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

Authors:  Lyndell L Lim; Frederick W Fraunfelder; James T Rosenbaum
Journal:  Arthritis Rheum       Date:  2007-10

9.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

10.  Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

Authors:  Michel De Bandt; Jean Sibilia; Xavier Le Loët; Sebastian Prouzeau; Bruno Fautrel; Christian Marcelli; Eric Boucquillard; Jean Louis Siame; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2005-03-01       Impact factor: 5.156
View more
  2 in total

Review 1.  A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

Authors:  Tânia Santiago; Mariana Galante Santiago; João Rovisco; Cátia Duarte; Armando Malcata; José António Pereira da Silva
Journal:  Clin Rheumatol       Date:  2013-08-17       Impact factor: 2.980

2.  Spondyloarthropathies in autoimmune diseases and vice versa.

Authors:  Oscar M Pérez-Fernández; Rubén D Mantilla; Paola Cruz-Tapias; Alberto Rodriguez-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2012-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.